BECN1 and malignant colon neoplasm: Other studies have also linked BECN1 overexpression with reduced survival in colon cancer patients treated with adjuvant 5-FU [26] and lower BECN1 expression with a longer median progression-free survival in patients with advanced colorectal cancer treated with cetuximab-containing chemotherapy [31].